Sugi Predict

Sugi Predict / Compounds / SCHEMBL7786247

SCHEMBL7786247

SCHEMBL7786247

CC(=O)c1cc(C)cc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.52
▸ RXRA P19793 1/20 0.49
▸ RXRB P28702 1/20 0.49
▸ RXRG P48443 1/20 0.49
▸ NOTUM Q6P988 1/20 0.42
▸ ADCY8 P40145 2/20 0.42
▸ ADCY1 Q08828 2/20 0.42
▸ KCNK3 O14649 1/20 0.42
▸ KCNK9 Q9NPC2 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ PGK1 P00558 1/20 0.41
▸ PGK2 P07205 1/20 0.41
▸ TAS2R14 Q9NYV8 1/20 0.41
▸ AKR1C3 P42330 1/20 0.41
▸ AKR1C2 P52895 1/20 0.41
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ TPMT P51580 1/20 0.40
▸ CA5A P35218 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96116 0.87 CES2 (0.67) CES2RXRARXRBRXRGNOTUM
SCHEMBL2926459 0.84 TPMT (0.61) CES2RXRARXRBRXRGNOTUM
SCHEMBL30240792 0.84 TPMT (0.61) CES2RXRARXRBRXRGNOTUM
SCHEMBL17586584 0.84 CES2 (0.57) CES2RXRARXRBRXRGNOTUM
Formaldehyde SCHEMBL459554 0.83 CES2 (0.61) CES2RXRARXRBRXRGNOTUM
SCHEMBL16962044 0.83 CES2 (0.45) CES2NOTUMADCY8ADCY1KCNK3
SCHEMBL12055235 0.82 CES2 (0.50) CES2NOTUMADCY8ADCY1KCNK3
SCHEMBL14405644 0.82 CES2 (0.50) CES2NOTUMADCY8ADCY1KCNK3
SCHEMBL16261236 0.82 RXRA (0.50) RXRARXRBRXRGKCNK3MAPT
SCHEMBL25795128 0.81 AKT1 (0.50) CES2NOTUMADCY8ADCY1KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382290-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-12-18 — — US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 — — US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 — — US disclosed
EP-4543450-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-30 — — EP disclosed
CN-119546304-A Salts of SOS1 inhibitors 米拉蒂治疗公司 2025-02-28 — — CN disclosed
US-20250059182-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS, INC 2025-02-20 — — US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 — — CN disclosed
CN-115135315-B SOS1 inhibitors 米拉蒂治疗股份有限公司 2024-11-26 — — CN disclosed
WO-2023250165-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-28 — — WO disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 — — US disclosed
US-20110229808-A1 CURL-FREE IMAGING MEMBERS WITH A SLIPPERY SURFACE XEROX CORPORATION (US) 2011-09-22 — — US disclosed
US-20110152318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2011-06-23 — — US disclosed
US-20110136049-A1 IMAGING MEMBERS COMPRISING FLUOROKETONE XEROX CORPORATION (US) 2011-06-09 — — US disclosed
US-20100240642-A1 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators SMITHKLINE BEECHAM CORPORATION (US) 2010-09-23 — — US disclosed
EP-1927596-A1 DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME Takeda Pharmaceutical Company Limited (JP) 2008-06-04 — — EP disclosed
US-20070270398-A1 New Compounds III ALBIREO AB (SE) 2007-11-22 — — US disclosed
EP-1487824-B1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-06-20 — — EP disclosed
EP-0735142-B1 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICALS CO LTD (JP) 2001-10-24 — — EP disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 — — US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382290-A1 SALTS OF SOS1 INHIBITORS SOS1, SOS2, SOST CES2 3989/4885RXRA 3802/4885RXRB 3570/4885
US-20110152318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME TRPV1, TRPA1, TRPV2 CES2 4660/4885RXRA 1568/4885RXRB 1797/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 CES2 4258/4885RXRA 3464/4885RXRB 2917/4885
US-20070270398-A1 New Compounds III CYP11B2, CYP11B1, SDHA CES2 2140/4885RXRA 3070/4885RXRB 2659/4885
US-20250059182-A1 SOS1 INHIBITORS SOS1, SOS2, SOST CES2 4247/4885RXRA 3369/4885RXRB 2991/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 CES2 4258/4885RXRA 3464/4885RXRB 2917/4885
US-20100240642-A1 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators PPARD, PPARA, PPARG CES2 1901/4885RXRA 36/4885RXRB 44/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST CES2 4247/4885RXRA 3369/4885RXRB 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.